Following the formation of Australia’s Arrotex through the merger of Apotex Australia and former Strides unit Arrow Pharmaceuticals, CEO Dennis Bastas sets out the firm’s priorities as a central player in the Australian market, as well as longer-term plans including potential future deals and reaching beyond Australia and into south-east Asia, in an exclusive interview with Generics Bulletin.
The creation of Arrotex marks the emergence of a new central player in the Australian generics market, born as a result of the merger between Apotex’ local business and former Strides unit Arrow Pharmaceuticals which closed on 10 July.
The combined company immediately became Australia’s largest generic pharmaceutical and private-label OTC business, with a market share of around 50%...
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
